BH3 MIMETICS

Name: INTERSTELLAR BLENDS
Address: 134 Vintage Park Blvd Ste A #331, Houston, TX, 77070, US
Telephone: +1-737-333-6345

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells
Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t (11; 14) multiple myeloma
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
A BH3 mimetic for killing cancer cells
ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2–Beclin1 interaction at endoplasmic reticulum
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells
BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells
In vitro effects of the BH3 mimetic,(−)-gossypol, on head and neck squamous cell carcinoma cells
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
A novel BH3 mimetic reveals a mitogen-activated protein kinase–dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
Reversal of cisplatin resistance with a BH3 mimetic,(−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B …
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic …
A novel BH3 mimetic S1 potently induces Bax/Bak‐dependent apoptosis by targeting both Bcl‐2 and Mcl‐1
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737
Structural Basis of Bcl‐xL Recognition by a BH3‐mimetic α/β‐Peptide Generated by Sequence‐Based Design
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells
The BH3 mimetic ABT-737 induces cancer cell senescence
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies
Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells
Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax
Endogenous Noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells
BH3-mimetic drugs: blazing the trail for new cancer medicines
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells
The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells
… is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101)
Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT …
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts
The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study
ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress
The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic–induced apoptosis
γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis …
Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the …
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53
The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
The BH3 mimetic obatoclax accumulates in lysosomes and causes their alkalinization
The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics
DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1, 4, 5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263
BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
Bcl-xL–inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores
… -induced apoptosis in non-small-cell lung cancer cells is dependent on Bax-and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 …
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling
S63845, an MCL-1 selective BH3 mimetic: another arrow in our quiver
The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737
SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells
HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells
S1, a novel pan- BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak
The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates …
Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis
Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells
The BH3‐mimetic ABT‐737 inhibits allogeneic immune responses
The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling
Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737
Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling
Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects
BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip1
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
Inhibition of JNK3 promotes apoptosis induced by BH3 mimetic S1 in chemoresistant human ovarian cancer cells
A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria
Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells
BH3‐domain mimetic compound BH3I‐2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria
Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in …
Defective autophagy in multidrug resistant cells may lead to growth inhibition by BH3‐mimetic gossypol
BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet …
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells
Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma
BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in …
Gamma-tocotrienol acts as a BH3 mimetic to induce apoptosis in neuroblastoma SH-SY5Y cells
Pancreatic cancer combination therapy using a BH3 mimetic and a synthetic tetracycline
… -of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic …
The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil
The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid
Canonical Bcl-2 motifs of the Na+/K+ pump revealed by the BH3 mimetic chelerythrine: early signal transducers of apoptosis?
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL
Pharmacological blockade of Bcl-2, Bcl-x L and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice
The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid …
Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737
Cytoprotective role of autophagy against BH3 mimetic gossypol in ATG5 knockout cells generated by CRISPR-Cas9 endonuclease
BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma
BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic flux
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA
The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed/refractory chronic lymphocytic leukemia: interim results of …
2-Deoxyglucose treatment complements the cisplatin-or BH3-only mimetic-induced suppression of neuroblastoma cell growth
BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition
Possible Mechanisms Of Resistance To The Novel BH3-mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk
Preliminary results of a phase II open-label, randomized study of the BH3 mimetic protein navitoclax (ABT-263) with or without rituximab for treatment of …
Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic
BH3 mimetic-elicited Ca 2+ signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca 2+-like peptides
Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer
BCL-2-Selective BH3 mimetic ABT-199 Is a potent agent for acute myeloid leukemia
Effect of the BH3 mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma
BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis
Pan‐ BH3 mimetic S1 Exhibits Broad‐Spectrum Antitumour Effects by Cooperation between Bax and Bak
BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma
Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells
Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies
The BH3-mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy.
A novel BH3 mimetic reveals a MAPK-dependent mechanism of melanoma cell survival controlled by p53 and reactive oxygen species
The pro-death role of autophagy and apoptosis in cell death induced by the BH3 mimetic gossypol
A small molecule BH3-mimetic suppresses cigarette smoke-induced mucous expression in airway epithelial cells
Computational analyses on delineating specificity of 2-hydroxy-3, 5-dinitrobenzamide, a BH3-mimetic, towards anti-apoptotic proteins
Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma
BH3 mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo
The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (−)‐gossypol to induce apoptosis in cancer cells with high level of Bcl‐2
Pushing cancer cells to commit suicide: Is 072RB, the new BH3 mimetic, up to the job?
BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
The BH3-mimetic obatoclax (GX15-070) posses a dual-mechanism of action and induces both apoptosis and autophagy-dependent cell death of B cell non-Hodgkin’s …
Combination therapy with BH3 mimetic and hyperthermia tends to be more effective on anti-melanoma treatment
Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737
Effect of the BH3 mimetic ABT-737 on human melanoma cells to apoptosis induced by selective BRAF inhibitors.
Nutrient starvation sensitizes human ovarian Cancer SKOV3 cells to BH3 mimetic via modulation of mitochondrial dynamics
Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).
Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells
Obatoclax, a BH3 mimetic, enhances cisplatin-induced apoptosis and decreases the clonogenicity of muscle invasive bladder cancer cells via mechanisms that involve …
Autophagy-mediated growth inhibition of malignant glioma cells by the BH3-mimetic gossypol
A Dual BH3-mimetic approach targeting BCL-2 and MCL1 is highly efficacious and well-tolerated in Acute Myeloid Leukemia
MIM1, the Mcl-1–specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells
Targeting the apoptotic machinery of pediatric acute lymphoblastic leukemia in vivo using the BH3-mimetic ABT-737
The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and …
BH3 mimetic Augments the Induction of Apoptosis by INNO-406, a Novel Bcr-Abl/Lyn Inhibitor, in Bcr-Abl+ Leukemic Cells.
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
Targeting the BCL-2 family of proteins in hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737
BCL-2 Phosphorylation Modulates Sensitivity to the BH3-mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic …
Disruption of Bcl-2 Heterodimerization by the BH3 mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML.
By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737
Intrinsic resistance of prostate cancer to the BH3 mimetic ABT-737 is related to expression of the anti-apoptotic Mcl-1 and additional survival and apoptosis regulating …
Studies of the combination of ABT-199, a BH3 mimetic that specifically targets Bcl-2 in combination with chemotherapy and the proteosome inhibitor bortezomib in” …
… 2 Dual Inhibitors Created by the Structure‐Based Hybridization of Drug‐Divided Building Blocks and a Fragment Deconstructed from a Known Two‐Face BH3 Mimetic
Bim–BH3-mimetic tHerapy for ra
RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines
BRAF inhibition is enhanced by BH3-mimetic through BIM induction.
Decoding The BH3-mimetic Pro-Apoptotic Activity Of Quercetin In Jurkat Cells
Novel BH3 mimetic based therapeutic strategies for the treatment of breast cancer
inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores− L Bcl-x
… FOR THE USE OF MCL1/BCL2 BH3 mimetic COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 mimetic ALONE …
Apoptosis mechanism induced by BH3 mimetic S1 in human leukemia cell line K562
Efficacy of the BH3-mimetic ABT-199 in acute lymphoblastic leukemia
To explore the use of a BH3-mimetic (ABT-737) as a chemosensitizer of osteosarcoma cells to doxorubicin.
Activity of the BH3 mimetic ABT-737 on Polycythemia Vera (PV) Erythroid Precursor Cells
Design and activity detection of BH3-mimetic peptide based on Bcl-XL binding potency
The BH3 mimetic navitoclax (ABT-263) selectively induces apoptosis in cholangiocarcinoma-associated fibroblasts thereby reducing tumor growth
Identification of Potent BH3-mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia
A p21Cip1-dependent autophagic cell death by BH3-mimetic gossypol in mutant BRAF melanoma cells (796.4)
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly
Maritoclax, a selective Mcl-1 inhibitor, sensitizes melanoma cells to the Bad BH3-mimetic ABT-737.
IDENTIFICATION OF POTENT BH3-mimetic COMBINATIONS TARGETING PRO-SURVIVAL PATHWAYS IN HUMAN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Relationship between BH3 mimetic S1 and expression of BCL-2 family members in acute myeloid leukemia
Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis
The BH3 mimetic GX015-070 (Obatoclax) induces apoptosis and growth inhibition in neoplastic mast cells
Induction of Bim by the BRAF inhibitor PLX4720 sensitizes human melanoma cells to the BH3 mimetic ABT-737
Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer
BH3-mimetic gossypol promotes autophagy to inhibit the proliferation of mutant BRAF melanoma cells with high expression of p21Cip1
Inhibition of prosurvival autophagy by the BH3-mimetic obatoclax sensitizes antiestrogen-resistant breast cancer cells to apoptosis
Failure of autophagy induction makes multidrug resistant cells vulnerable to BH3-mimetic gossypol
Abstract A28: Apoptosis induction with the MEK inhibitor AZD6244 and BH3 mimetic ABT-737 in melanoma.
PL-09. MEDULLOBLASTOMA IS PRIMED FOR RAPID APOPTOSIS BY CONSTITUTIVELY ACTIVE BAX AND IS HIGHLY SENSITIVE TO BH3 mimetic THERAPY
Functional disparity among BCL-2 members in tonsillar and leukemic B cell subsets probed by next generation BH3 mimetic profiling
695 The BH3 Mimetic, Small Molecule, ABT-737, Was Effective As Lympholytic Therapy in the MRL/lpr-/-Mouse Model of Autoimmune Lymphoproliferative Syndrome …
S1, a Bid-like BH3 mimetic, induces apoptosis by dynamic change of Mcl-1 and dependent on Bak, not Bax
Acquired cisplatin resistance in malignant pleural mesothelioma cells is reversed by both BH3-mimetic obatoclax and IAP-inhibitor AT-406
Broad spectrum BH3 mimetic BI-97D6 induces apoptosis of acute myeloid leukemia cells even when co-cultured with supporting stromal cells
ABT-737, A BH3 MIMETIC, LEADS TO RADIOSENSITIZATION OF HEAD AND NECK SQUAMOUS CELL CARCINOMA VIA INDUCTION OF INTRAMITOCHONDRIAL …
The BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptosis by releasing Bim and Bak proteins in human pancreatic cancer cells
Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 mimetic ABT-737 Has Synergistic Anti-Myeloma Activity
Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
A potent BH3 mimetic targeting BCL-XL induces apoptosis regulated by PTEN loss and integrin alpha 5 in prostate cancer cells
The BH3 mimetic Obatoclax (GX015-070) synergistically enhances TRAIL-mediated apoptosis by activating Bak and Bax in human pancreatic cancer cells
Identification of a novel mechanism by which the BH3 mimetic obatoclax sensitizes non-Hodgkin’s lymphoma tumor cells to TRAIL-mediated apoptosis
The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
Combining the anti-mesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cell lines.
The BH3 Mimetic, Small Molecule, ABT-737, Was Effective As Lympholytic Therapy in the MRL/lpr−/− Mouse Model of Autoimmune Lymphoproliferative Syndrome …
The BH3-mimetic ABT-737 Reverses the Intrinsic Radioresistance of Head and Neck Squamous Carcinoma Stem and Non-stem Cells
Abstract LB-23: In vivo exposure of infant leukemia to the BH3-mimetic ABT-263 selects for a cell death-resistant phenotype
Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines
Abstract B26: Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts
Possible molecular mechanisms and pathways involved in BH3 mimetic activity of alpha-lipoic acid on human colon cancer cell line
S110 (−)-Gossypol, a BH3 mimetic and Inducer of Apoptosis in Head and Neck Cancer Cells, Is Oxidized and Deactivated by ROS
S63845, a novel BH3 mimetic Mcl-1 inhibitor synergizes with midostaurin to induce potent apoptosis in acute myeloid leukemia cells carrying FLT3-ITD mutations
A short term biomarker-based assay predicts apoptotic response to combined BCL-2/MCL-1 BH3 mimetic targeting in Myeloma cells
Supplemental data Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Abstract# 374: BH3 mimetic, ABT-737, enhances celecoxib-induced apoptosis that can be further augmented by inhibition of autophagy in human colon cancer cells.
Abstract# 2786: Apoptosis induced by JAK2 inhibition requires Bim and is enhanced by a BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells
BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
Mechanisms underlying synergistic interactions between the CDK inhibitor flavopiridol (Alvocidib) and the BH3 mimetic GX15-070 (Obatoclax) in human multiple …
The BH3-mimetic GX15-070 induces autophagy-dependent cell death of therapy-sensitive and-resistant aggressive B cell non-Hodgkin’s lymphoma (B-NHL)
The BH3 mimetic compound BH3I-1 impairs mitochondrial dynamics and promotes stress response in addition to its pro-apoptotic key function
P2. 05-004 ABT-737, a BH3 Mimetic, Enhances Therapeutic Effect of Ionizing Radiation in Murine Lung Cancer Model: Topic: Biology
The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid …
Synergistic cytotoxic/apoptotic effects of AT-101, a phytochemical with BH3-mimetic property, in combination with paclitaxel in human breast cancer cells.
Cover Picture: Structural Basis of Bcl‐xL Recognition by a BH3‐mimetic α/β‐Peptide Generated by Sequence‐Based Design (ChemBioChem 13/2011)
Examination of 4-hydroxy tamoxifen-and BH3 mimetic-induced cell death pathways in glioblastoma and malignant peripheral nerve sheath tumor cells
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma
Supplemental data The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Abstract# 3276: The BH3 mimetic Obatoclax (GX15-070) sensitized B-NHL cells to TRAIL-mediated apoptosis by activating Bak and inhibiting Mcl-1, NF-\# 954; B and …
Compounds and methods for inducing apoptosis in cancer cells using a BH3 alpha-helical mimetic

BH3 MIMETICS

P53

(Reverses | Reversal Of | Reverse | Reversed) Obesity

Cd36

support@interstellarblends.com